Aptorum Group Limited Class A - ADR
$8.41
$0.09
(1.08%)
As on 27-Jul-2026 09:30EDT
Market cap
$1 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-7.1
-
Face value
--
-
Shares outstanding
634,682
8 Years Aggregate
CFO
$-82.64 Mln
EBITDA
$-95.29 Mln
Net Profit
$-66.73 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aptorum Group Limited Class A - ADR
| -20.7 | 8.7 | -6.2 | -53.5 | -25.6 | -50.0 | -- |
|
BSE Sensex*
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Aptorum Group Limited Class A - ADR
| -62.1 | -55.5 | -63.3 | -39.3 | -84.4 | 4.4 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aptorum Group Limited Class A - ADR
|
8.4 | 0.6 | 1.0 | -5.7 | 0.0 | -49 | -- | 0.3 |
| 17.1 | 885.2 | 104.3 | 53.8 | 61.6 | 18.4 | 16.4 | 3.1 |
Shareholding Pattern
View DetailsAbout Aptorum Group Limited Class A - ADR
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include... SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Read more
-
Founder, CEO & Non-Executive Director
Mr. Chung Yuen Huen
-
Founder, CEO & Non-Executive Director
Mr. Chung Yuen Huen
-
Headquarters
Princeton, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Aptorum Group Limited Class A - ADR
What is the current share price of Aptorum Group Limited Class A - ADR Today?
The share price of Aptorum Group Limited Class A - ADR is $8.41 (NASDAQ) as of 27-Jul-2026 09:30 EDT. Aptorum Group Limited Class A - ADR has given a return of -25.57% in the last 3 years.
What is the current PB & PE ratio of Aptorum Group Limited Class A - ADR?
Since, TTM earnings of Aptorum Group Limited Class A - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-5.72 |
0.34 |
2024 |
-0.37 |
0.07 |
2023 |
-0.33 |
0.04 |
2022 |
-0.02 |
0.01 |
2021 |
-2.13 |
2.26 |
What is the 52 Week High and Low of Aptorum Group Limited Class A - ADR?
The 52-week high and low of Aptorum Group Limited Class A - ADR are Rs 74.90 and Rs 6.10 as of 31-Aug-2026.
What is the market cap of Aptorum Group Limited Class A - ADR?
Aptorum Group Limited Class A - ADR has a market capitalisation of $ 1 Mln as on 27-Jul-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Aptorum Group Limited Class A - ADR?
Before investing in Aptorum Group Limited Class A - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.